Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | SOX18 | P35713 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL967191 | 1.00 | SIGMAR1 (0.35) | SIGMAR1CYP1A2CYP2A6HTR2AHTR2C | |
| SCHEMBL970714 | 0.88 | HTR2A (0.41) | SIGMAR1CYP1A2CYP2A6HTR2AHTR2C | |
| SCHEMBL7552716 | 0.85 | PRSS1 (0.34) | CYP1A2 | |
| SCHEMBL4494121 | 0.85 | PRSS1 (0.34) | CYP1A2 | |
| SCHEMBL4494128 | 0.85 | PRSS1 (0.34) | CYP1A2 | |
| SCHEMBL7552725 | 0.85 | PRSS1 (0.34) | CYP1A2 | |
| SCHEMBL966114 | 0.79 | AGXT (0.40) | HTR2B | |
| SCHEMBL966115 | 0.79 | AGXT (0.40) | HTR2B | |
| SCHEMBL4415054 | 0.79 | AGXT (0.40) | CYP2A6CASR | |
| SCHEMBL4415050 | 0.79 | AGXT (0.40) | CYP2A6CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872045-B2 | Treating ocular hypertension, glaucoma, by administering prostaglandin derivatives such as {3-[(1R,2S,3R)-3-Hydroxy-2-((S)-(E)-3-(hydroxy)-5-(naphthyl)pent-1-enyl)-5-oxocyclopentylsulfanyl]propylsulfanyl}acetic acid methyl ester | ALLERGAN, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1395263-B1 | 3, 7 OR 3 AND 7 THIA OR OXA PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2009-12-30 | — | — | EP | disclosed |
| US-7183324-B2 | 2,3,4-substituted cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183324-B2 | 2,3,4-substituted cyclopentanones as therapeutic agents | ALLERGAN, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| WO-2007001671-A1 | USE OF 3- OR 7-THIA- OR 3 , 7-DITΗIAPR0STEN0IC ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-6956057-B2 | EP4 agonists as agents for lowering intraocular pressure | ALLERGAN, INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050222094-A1 | Treatment of inflammatory bowel disease | ALLERGAN, INC. | 2005-10-06 | — | — | US | disclosed |
| US-20050209194-A1 | Combination therapy for glaucoma treatment | ALLERGAN, INC. | 2005-09-22 | — | — | US | disclosed |
| US-20040102499-A1 | EP4 agonists as agents for lowering intraocular pressure | ALLERGAN, INC. | 2004-05-27 | — | — | US | disclosed |
| EP-1395263-A1 | 3, 7 OR 3 AND 7 THIA OR OXA PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | Allergan, Inc. (US) | 2004-03-10 | — | — | EP | disclosed |
| US-6538018-B1 | Method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound | ALLERGAN, INC. | 2003-03-25 | — | — | US | disclosed |
| WO-2002102389-A1 | 3, 7 OR 3 AND 7 THIA OR OXA PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222094-A1 | Treatment of inflammatory bowel disease | SLC10A2, NR1H4, FABP2 | SIGMAR1 1318/4885CYP1A2 1007/4885CYP2A6 1292/4885 |
| US-20050209194-A1 | Combination therapy for glaucoma treatment | RHOXF2, EDNRB, PDE6D | SIGMAR1 3367/4885CYP1A2 1924/4885CYP2A6 2417/4885 |
| US-20040102499-A1 | EP4 agonists as agents for lowering intraocular pressure | PTGER4, PTGIR, PTGER1 | SIGMAR1 2661/4885CYP1A2 1506/4885CYP2A6 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.